We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

76 hedge funds and large institutions have $88.1M invested in Aevi Genomic Medicine Inc in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 15 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,853% more call options, than puts

Call options by funds: $6.58M | Put options by funds: $337K

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

67% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 15

12% more funds holding

Funds holding: 68 → 76 (+8)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3% less capital invested

Capital invested by funds: $91.2M → $88.1M (-$3.13M)

Holders
76
Holders Change
+8
Holders Change %
+11.76%
% of All Funds
1.9%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
25
Reduced
15
Closed
6
Calls
$6.58M
Puts
$337K
Net Calls
+$6.24M
Net Calls Change
+$5.86M

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$1.91M
2
BFA
BlackRock Fund Advisors
California
+$745K
3
Morgan Stanley
Morgan Stanley
New York
+$390K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$386K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$362K

Top Sellers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
-$1.58M
2
QF
QVT Financial
New York
-$688K
3
SS
Sunbelt Securities
Texas
-$223K
4
TD Asset Management
TD Asset Management
Ontario, Canada
-$203K
5
BFM
Boothbay Fund Management
New York
-$84K
Name Holding Trade Value Shares
Change 		Change in
Stake
VOYA Investment Management
51
VOYA Investment Management
Georgia
$65K – – –
Group One Trading
52
Group One Trading
Illinois
$53K +$54K +10,253 New
Creative Planning
53
Creative Planning
Kansas
$52K +$26.3K +5,000 +100%
Legal & General Group
54
Legal & General Group
United Kingdom
$40K +$16.4K +3,114 +68%
UBS Group
55
UBS Group
Switzerland
$31K +$7.05K +1,340 +28%
Bank of America
56
Bank of America
North Carolina
$30K +$18.8K +3,574 +162%
SO
57
STRS Ohio
Ohio
$26K – – –
PCM
58
Penserra Capital Management
California
$24K +$2.42K +460 +11%
PVH
59
Psagot Value Holdings
Israel
$22K -$8.85K -1,681 -28%
Victory Capital Management
60
Victory Capital Management
Texas
$20K +$1.69K +322 +9%
TRCT
61
Tower Research Capital (TRC)
New York
$20K +$20.4K +3,870 New
Royal Bank of Canada
62
Royal Bank of Canada
Ontario, Canada
$19K +$9K +1,710 +86%
MAM
63
Meeder Asset Management
Ohio
$13K +$12.9K +2,445 New
LA
64
Legacy Advisors
Pennsylvania
$12K +$12.9K +2,450 New
BlackRock
65
BlackRock
New York
$9K -$2.26K -430 -20%
Citigroup
66
Citigroup
New York
$6K +$5.81K +1,104 New
BKA
67
Brick & Kyle Associates
Pennsylvania
$5K – – –
TWA
68
TCI Wealth Advisors
Arizona
$5K – – –
KTC
69
Kistler-Tiffany Companies
Pennsylvania
$4K – – –
IA
70
IFP Advisors
Florida
$3K -$158 -30 -6%
AG
71
Advisor Group
Arizona
$3K – – –
Simplex Trading
72
Simplex Trading
Illinois
$3K +$942 +179 +34%
IWM
73
IHT Wealth Management
Illinois
$3K +$2.63K +500 New
LTFS
74
Ladenburg Thalmann Financial Services
Florida
$2K – – –
Northwestern Mutual Wealth Management
75
Northwestern Mutual Wealth Management
Wisconsin
$1K +$1.05K +200 New
1 2
3
4

GNMX Hedge Fund Activity: Q4 2016 in Review

76 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q4 2016, worth a combined $88.1M — down 3.4% from $91.2M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new GNMX positions and 6 closed out — a net gain of 8 holders — while 25 added to existing stakes and 15 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $1.91M. The largest seller was Opaleye Management, cutting an estimated $1.58M.

  • 76 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q4 2016, up from 68 in Q3 2016.
  • Funds reported $88.1M of Aevi Genomic Medicine Inc stock for Q4 2016, down 3.4% quarter-over-quarter.
  • 14 funds opened new Aevi Genomic Medicine Inc positions in Q4 2016 and 6 closed out, a net change of +8 holders.
  • The largest Aevi Genomic Medicine Inc buyer in Q4 2016 was Millennium Management, an estimated $1.91M added.
  • The largest Aevi Genomic Medicine Inc seller in Q4 2016 was Opaleye Management, an estimated $1.58M sold.

Based on aggregated 13F filings for Q4 2016.